Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: A retrospective immunohistochemical study

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3839-3847

  Ray, Partha S ^a   Bagaria, Sanjay P ^a   Wang, Jinhua ^a   Shamonki, Jaime M ^b   Ye, Xing ^a   Sim, Myung Shin ^a   Steen, Shawn ^a   Qu, Ying ^a   Cui, Xiaojiang ^a   Giuliano, Armando E ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; TRANSCRIPTION FACTOR FOXC1;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 82955236210     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1657-8     Document Type: Article

References (26)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
2. SH Dairkee L Puett AJ Hackett 1988 Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue J Natl Cancer Inst. 80 691 695 2453676 10.1093/jnci/80.9.691 1:STN:280: DyaL1c3jtVGjtA%3D%3D
3. RHW Wetzels R Holland 1989 Haelst UJGMv, et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast Am J Pathol 134 571 579 2466404 1:STN:280: DyaL1M7msVCiuw%3D%3D (Pubitemid 19082851)
4. FC Bidard R Conforti T Boulet, et al. 2007 Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 "triple-negative" breast cancers Ann Oncol. 18 1285 1286 17675400 10.1093/annonc/mdm360 (Pubitemid 47244379)
5. EA Rakha DS Tan WD Foulkes, et al. 2007 Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 9 404 18279542 10.1186/bcr1827
6. E Rakha I Ellis J Reis-Filho 2008 Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res. 14 618 18223240 10.1158/1078-0432. CCR-07-1943 (Pubitemid 351226133)
7. F Bertucci P Finetti N Cervera, et al. 2008 How basal are triple-negative breast cancers? Int J Cancer. 123 236 240 18398844 10.1002/ijc.23518 1:CAS:528:DC%2BD1cXmtlantbg%3D (Pubitemid 351705215)
8. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA. 295 2492 2502 16757721 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D (Pubitemid 43854964)
9. CU Ihemelandu LD Leffall Jr RL Dewitty, et al. 2007 Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival J Surg Res. 143 109 118 17950079 10.1016/j.jss.2007.03.085 1:CAS:528:DC%2BD2sXhtF2htrbN (Pubitemid 47562451)
10. CU Ihemelandu TJ Naab HM Mezghebe, et al. 2008 Treatment and survival outcome for molecular breast cancer subtypes in black women Ann Surg. 247 463 469 18376191 10.1097/SLA.0b013e31815d744a
11. R Dent M Trudeau KI Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res. 13 15 Pt 1 4429 4434 17671126 10.1158/1078-0432.CCR-06-3045 (Pubitemid 47219710)
12. M Smid Y Wang Y Zhang, et al. 2008 Subtypes of breast cancer show preferential site of relapse Cancer Res. 68 3108 3114 18451135 10.1158/0008-5472.CAN-07-5644 1:CAS:528:DC%2BD1cXltlSmt7Y%3D
13. EA Rakha SE Elsheikh MA Aleskandarany, et al. 2009 Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res. 15 2302 2310 19318481 10.1158/1078-0432.CCR-08-2132 1:CAS:528:DC%2BD1MXjvVWltbs%3D
14. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res. 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
15. MC Cheang D Voduc C Bajdik, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res. 14 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D (Pubitemid 351413917)
16. SE Elsheikh AR Green EA Rakha, et al. 2008 Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype Br J Cancer. 99 327 334 18612310 10.1038/sj.bjc.6604463 1:CAS:528: DC%2BD1cXosFWntrY%3D
17. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol. 26 2568 2581 18487574 10.1200/JCO.2007.13.1748
18. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A. 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
19. PS Ray J Wang Y Qu, et al. 2010 FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer Cancer Res. 70 3870 3876 20406990 10.1158/0008-5472.CAN-09-4120 1:CAS:528:DC%2BC3cXlvFyrtL8%3D
20. LM McShane DG Altman W Sauerbrei, et al. 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer. 93 387 391 16106245 10.1038/sj.bjc.6602678 1:CAS:528:DC%2BD2MXnvFymtLo%3D (Pubitemid 43080010)
21. H Yaziji LC Goldstein TS Barry, et al. 2004 HER-2 testing in breast cancer using parallel tissue-based methods JAMA. 291 1972 1977 15113815 10.1001/jama.291.16.1972 1:CAS:528:DC%2BD2cXjs1ajtrk%3D (Pubitemid 38544278)
22. M Laakso M Tanner J Nilsson, et al. 2006 Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer Clin Cancer Res 12 14 Pt 1 4185 4191 16857790 10.1158/1078-0432.CCR-06- 0353 1:CAS:528:DC%2BD28XntFSms7o%3D
23. JM Bland DG Altman 1998 Survival probabilities (the Kaplan-Meier method) BMJ 317 7172 1572 9836663 10.1136/bmj.317.7172.1572 1:STN:280: DyaK1M%2FlsFaitQ%3D%3D (Pubitemid 128719735)
24. JM Bland DG Altman 2004 The logrank test BMJ 328 7447 1073 15117797 10.1136/bmj.328.7447.1073
25. H Akaike 1974 A new look at the statistical model identification IEEE Trans Automatic Control. 19 716 723 10.1109/TAC.1974.1100705
26. E Dejeux JA Ronneberg H Solvang, et al. 2010 DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response Mol Cancer. 9 68 20338046 10.1186/1476-4598-9-68